NO331454B1 - Farmasoytisk preparat for oral administrering omfattende deskarbonyletoksyloratadin - Google Patents

Farmasoytisk preparat for oral administrering omfattende deskarbonyletoksyloratadin Download PDF

Info

Publication number: NO331454B1
Authority: NO; Norway
Prior art keywords: amount; descarbonylethoxyloratadine; pharmaceutical preparation; pharmaceutically acceptable; weight
Prior art date: 1998-07-10

Application number

NO20005485A

Other languages

English (en)

Norwegian (no)

Other versions

NO20005485D0 (no

NO20005485L (no

Inventor

Jim H Kou

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

2000-10-31

Publication date

2012-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22348307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331454(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-10-31 Application filed by Schering Corp filed Critical Schering Corp

2000-10-31 Publication of NO20005485D0 publication Critical patent/NO20005485D0/no

2001-03-09 Publication of NO20005485L publication Critical patent/NO20005485L/no

2012-01-09 Publication of NO331454B1 publication Critical patent/NO331454B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 46
150000001447 alkali salts Chemical class 0.000 claims abstract description 16
229920002472 Starch Polymers 0.000 claims abstract description 11
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 11
238000004090 dissolution Methods 0.000 claims abstract description 11
239000008107 starch Substances 0.000 claims abstract description 11
235000019698 starch Nutrition 0.000 claims abstract description 11
239000003795 chemical substances by application Substances 0.000 claims abstract description 10
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 9
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 9
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 9
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 9
230000001681 protective effect Effects 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 26
238000002360 preparation method Methods 0.000 claims description 19
230000003266 anti-allergic effect Effects 0.000 claims description 17
239000000546 pharmaceutical excipient Substances 0.000 claims description 14
239000003937 drug carrier Substances 0.000 claims description 11
230000002378 acidificating effect Effects 0.000 claims description 8
235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 4
239000007884 disintegrant Substances 0.000 claims description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
229910052791 calcium Inorganic materials 0.000 claims description 3
239000011777 magnesium Substances 0.000 claims description 3
229910052749 magnesium Inorganic materials 0.000 claims description 3
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
241000124008 Mammalia Species 0.000 abstract description 5
206010020751 Hypersensitivity Diseases 0.000 abstract description 4
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 abstract description 2
239000003826 tablet Substances 0.000 description 33
239000000843 powder Substances 0.000 description 19
238000000034 method Methods 0.000 description 12
238000009472 formulation Methods 0.000 description 11
229920002261 Corn starch Polymers 0.000 description 9
239000008120 corn starch Substances 0.000 description 9
229940099112 cornstarch Drugs 0.000 description 9
238000005469 granulation Methods 0.000 description 8
230000003179 granulation Effects 0.000 description 8
239000000463 material Substances 0.000 description 7
235000021355 Stearic acid Nutrition 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000000354 decomposition reaction Methods 0.000 description 6
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
239000008117 stearic acid Substances 0.000 description 6
239000004480 active ingredient Substances 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
238000000576 coating method Methods 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000007916 tablet composition Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
230000001387 anti-histamine Effects 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
239000000739 antihistaminic agent Substances 0.000 description 3
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 3
238000013098 chemical test method Methods 0.000 description 3
229960001021 lactose monohydrate Drugs 0.000 description 3
229960003088 loratadine Drugs 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
238000002845 discoloration Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000011194 good manufacturing practice Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000000391 magnesium silicate Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
229940095672 calcium sulfate Drugs 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000011436 cob Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
239000011874 heated mixture Substances 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
239000012535 impurity Substances 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229940033134 talc Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Biophysics (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20005485A 1998-07-10 2000-10-31 Farmasoytisk preparat for oral administrering omfattende deskarbonyletoksyloratadin NO331454B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US11323298A	1998-07-10	1998-07-10
PCT/US1999/012368 WO2000002560A1 (en)	1998-07-10	1999-07-08	8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO[5,6]CYCLOHEPTA[1,2-b]PYRIDINE ORAL COMPOSITIONS

Publications (3)

Publication Number	Publication Date
NO20005485D0 NO20005485D0 (no)	2000-10-31
NO20005485L NO20005485L (no)	2001-03-09
NO331454B1 true NO331454B1 (no)	2012-01-09

Family

ID=22348307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20005485A NO331454B1 (no)	1998-07-10	2000-10-31	Farmasoytisk preparat for oral administrering omfattende deskarbonyletoksyloratadin

Country Status (27)

Country	Link
EP (3)	EP1073438B1 (cs)
JP (4)	JP3224379B1 (cs)
KR (1)	KR100420641B1 (cs)
CN (1)	CN1145485C (cs)
AR (4)	AR016044A1 (cs)
AT (2)	ATE262904T1 (cs)
AU (1)	AU741201B2 (cs)
BR (1)	BR9910449A (cs)
CA (2)	CA2377178A1 (cs)
CY (1)	CY1109279T1 (cs)
CZ (1)	CZ300843B6 (cs)
DE (2)	DE69916042T2 (cs)
DK (2)	DK1380297T3 (cs)
ES (2)	ES2214871T3 (cs)
HU (1)	HU228448B1 (cs)
ID (1)	ID28645A (cs)
IL (1)	IL139407A0 (cs)
MY (1)	MY116038A (cs)
NO (1)	NO331454B1 (cs)
NZ (2)	NZ507885A (cs)
PE (1)	PE20000761A1 (cs)
PL (1)	PL199390B1 (cs)
PT (2)	PT1380297E (cs)
SK (1)	SK288240B6 (cs)
TW (1)	TW575424B (cs)
WO (1)	WO2000002560A1 (cs)
ZA (1)	ZA200006224B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001045668A2 (en)	1999-12-20	2001-06-28	Schering Corporation	Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
WO2001045676A2 (en) *	1999-12-20	2001-06-28	Schering Corporation	Extended release oral dosage composition
US7405223B2 (en)	2000-02-03	2008-07-29	Schering Corporation	Treating allergic and inflammatory conditions
US7507714B2 (en)	2000-09-27	2009-03-24	Bayer Corporation	Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
AU2005263958B2 (en) *	2004-07-16	2011-04-14	Cipla Limited	Anti-histaminic composition
EP2181994B1 (en)	2006-03-31	2014-05-28	Research Foundation Itsuu Laboratory	Antimicrobial compounds
US8377995B2 (en)	2007-11-21	2013-02-19	Dainippon Sumitomo Pharma Co., Ltd.	Orally disintegrating tablet
TR200806298A2 (tr)	2008-08-22	2010-03-22	Bi̇lgi̇ç Mahmut	Farmasötik formülasyon
EP2269586B1 (en)	2009-07-01	2011-09-21	Alfred E. Tiefenbacher (GmbH & Co. KG)	Pharmaceutical composition comprising desloratadine
PT2568970T (pt)	2010-05-10	2019-02-11	Lesvi Laboratorios Sl	Formulações farmacêuticas estáveis contendo um anti-histamínico

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61501205A (ja)	1984-02-15	1986-06-19	シェリング・コ−ポレ−ション	８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4657716A (en)	1984-03-19	1987-04-14	Lim Kunststoff Technologie Gesellschaft	Method of making elastomeric shoe soles
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5595997A (en)	1994-12-30	1997-01-21	Sepracor Inc.	Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
TW522014B (en) *	1997-02-07	2003-03-01	Sepracor Inc	Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine

1999
- 1999-07-08 JP JP2000558820A patent/JP3224379B1/ja not_active Expired - Lifetime
- 1999-07-08 KR KR10-2000-7012430A patent/KR100420641B1/ko not_active Expired - Lifetime
- 1999-07-08 DK DK03023240T patent/DK1380297T3/da active
- 1999-07-08 AT AT99933484T patent/ATE262904T1/de active
- 1999-07-08 CA CA002377178A patent/CA2377178A1/en not_active Abandoned
- 1999-07-08 AT AT03023240T patent/ATE432075T1/de active
- 1999-07-08 CN CNB998068497A patent/CN1145485C/zh not_active Expired - Lifetime
- 1999-07-08 PL PL344045A patent/PL199390B1/pl unknown
- 1999-07-08 SK SK1711-2000A patent/SK288240B6/sk not_active IP Right Cessation
- 1999-07-08 DE DE69916042T patent/DE69916042T2/de not_active Expired - Lifetime
- 1999-07-08 AU AU49531/99A patent/AU741201B2/en not_active Expired
- 1999-07-08 DE DE69940932T patent/DE69940932D1/de not_active Expired - Lifetime
- 1999-07-08 NZ NZ507885A patent/NZ507885A/en not_active IP Right Cessation
- 1999-07-08 HU HU0101900A patent/HU228448B1/hu unknown
- 1999-07-08 ID IDW20010070A patent/ID28645A/id unknown
- 1999-07-08 WO PCT/US1999/012368 patent/WO2000002560A1/en not_active Ceased
- 1999-07-08 NZ NZ512916A patent/NZ512916A/xx not_active IP Right Cessation
- 1999-07-08 CZ CZ20004056A patent/CZ300843B6/cs unknown
- 1999-07-08 DK DK99933484T patent/DK1073438T3/da active
- 1999-07-08 IL IL13940799A patent/IL139407A0/xx not_active IP Right Cessation
- 1999-07-08 ES ES99933484T patent/ES2214871T3/es not_active Expired - Lifetime
- 1999-07-08 PT PT03023240T patent/PT1380297E/pt unknown
- 1999-07-08 PT PT99933484T patent/PT1073438E/pt unknown
- 1999-07-08 EP EP99933484A patent/EP1073438B1/en not_active Revoked
- 1999-07-08 BR BR9910449-0A patent/BR9910449A/pt not_active Application Discontinuation
- 1999-07-08 CA CA002325014A patent/CA2325014C/en not_active Expired - Lifetime
- 1999-07-08 AR ARP990103342A patent/AR016044A1/es not_active Application Discontinuation
- 1999-07-08 ES ES03023240T patent/ES2326214T3/es not_active Expired - Lifetime
- 1999-07-08 EP EP03023240A patent/EP1380297B1/en not_active Expired - Lifetime
- 1999-07-08 EP EP09002742A patent/EP2055303A3/en not_active Withdrawn
- 1999-07-09 MY MYPI99002889A patent/MY116038A/en unknown
- 1999-07-09 PE PE1999000697A patent/PE20000761A1/es not_active IP Right Cessation
- 1999-07-09 TW TW088111680A patent/TW575424B/zh not_active IP Right Cessation
2000
- 2000-07-17 AR ARP000103669A patent/AR021159A1/es not_active Application Discontinuation
- 2000-07-17 AR ARP000103668A patent/AR021158A2/es unknown
- 2000-07-17 AR ARP000103667A patent/AR021157A2/es unknown
- 2000-10-31 NO NO20005485A patent/NO331454B1/no not_active IP Right Cessation
- 2000-11-01 ZA ZA200006224A patent/ZA200006224B/xx unknown
2001
- 2001-07-04 JP JP2001204138A patent/JP4160739B2/ja not_active Expired - Lifetime
2005
- 2005-07-08 JP JP2005200665A patent/JP4621082B2/ja not_active Expired - Lifetime
2009
- 2009-08-10 CY CY20091100846T patent/CY1109279T1/el unknown
2010
- 2010-08-26 JP JP2010190099A patent/JP2010265329A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AR021158A2 (es)	2002-06-12
HU228448B1 (en)	2013-03-28
ATE432075T1 (de)	2009-06-15
SK17112000A3 (sk)	2001-12-03
EP1073438B1 (en)	2004-03-31
KR100420641B1 (ko)	2004-03-02
AR016044A1 (es)	2001-06-20
EP1380297B1 (en)	2009-05-27
ES2214871T3 (es)	2004-09-16
IL139407A (en)	2001-10-31
CA2325014C (en)	2002-05-28
JP2005298524A (ja)	2005-10-27
CA2377178A1 (en)	2000-01-20
PL199390B1 (pl)	2008-09-30
DE69940932D1 (de)	2009-07-09
BR9910449A (pt)	2001-01-02
JP4160739B2 (ja)	2008-10-08
JP2002520285A (ja)	2002-07-09
HUP0101900A2 (hu)	2001-11-28
ZA200006224B (en)	2001-11-01
SK288240B6 (sk)	2015-02-03
DE69916042T2 (de)	2004-11-11
AR021159A1 (es)	2002-06-12
PL344045A1 (en)	2001-09-24
TW575424B (en)	2004-02-11
WO2000002560A1 (en)	2000-01-20
EP2055303A3 (en)	2009-12-16
AU4953199A (en)	2000-02-01
ID28645A (id)	2001-06-21
IL139407A0 (en)	2001-11-25
NZ512916A (en)	2003-03-28
DE69916042D1 (de)	2004-05-06
DK1073438T3 (da)	2004-05-10
ES2326214T3 (es)	2009-10-05
DK1380297T3 (da)	2009-08-17
CY1109279T1 (el)	2012-05-23
EP1073438A1 (en)	2001-02-07
JP3224379B1 (ja)	2001-10-29
CZ20004056A3 (cs)	2001-03-14
CZ300843B6 (cs)	2009-08-26
PT1380297E (pt)	2009-07-06
AR021157A2 (es)	2002-06-12
AU741201B2 (en)	2001-11-22
CN1145485C (zh)	2004-04-14
HK1030361A1 (en)	2001-05-04
KR20010043402A (ko)	2001-05-25
JP4621082B2 (ja)	2011-01-26
NO20005485D0 (no)	2000-10-31
MY116038A (en)	2003-10-31
EP1380297A1 (en)	2004-01-14
JP2010265329A (ja)	2010-11-25
HUP0101900A3 (en)	2003-01-28
JP2002068983A (ja)	2002-03-08
ATE262904T1 (de)	2004-04-15
PE20000761A1 (es)	2000-08-31
NO20005485L (no)	2001-03-09
EP2055303A2 (en)	2009-05-06
PT1073438E (pt)	2004-07-30
CA2325014A1 (en)	2000-01-20
NZ507885A (en)	2001-08-31
CN1303284A (zh)	2001-07-11

Legal Events

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2019-08-12

MK1K

Patent expired

Publication	Publication Date	Title
US6100274A (en)	2000-08-08	8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
JP2010265329A (ja)	2010-11-25	８−クロロ−６，１１−ジヒドロ−１１−（４−ピペリジリデン）−５Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジンの経口用組成物
NO311918B1 (no)	2002-02-18	Filmbelagt tablett av astemizol og pseudoefedrin, med forlenget frigivelse, samt fremgangsmåte ved fremstilling av denne
MXPA03005883A (es)	2005-04-19	Composiciones farmaceuticas que comprenden maleato de amlodipina.
KR100846945B1 (ko)	2008-07-17	파라세타몰을 포함하는 연하 정제
HUP0600237A2 (en)	2006-11-28	Pharmaceutical tablet comprising paroxetine mesylate
JP4824224B2 (ja)	2011-11-30	糖衣製剤
MXPA00011159A (en)	2001-07-31	8-chloro-6,11-dihydro-11- (4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions
HK1129313A (en)	2009-11-27	8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo [5,6] cyclohepta [1,2-b] pyridine oral compositions
HK1030361B (en)	2004-07-23	8-chloro-6,11-dihydro-11-(4-piperidylidine)-5h-benzo (5,6) cyclohepta(1,2-b)pyridine oral compositions
CS276556B6 (en)	1992-06-17	Pharmaceutical with a controllable bio-disposal of active component
KR101852856B1 (ko)	2018-04-27	비타민 d 또는 그 유도체를 함유하는 과립 및 상기 과립과 라록시펜을 포함하는 복합 캡슐제
PL199813B1 (pl)	2008-11-28	Stały doustny preparat farmaceutyczny acebutololu o przedłużonym uwalnianiu i sposób jego wytwarzania
SK15612000A3 (sk)	2002-05-09	Perorálne tablety s riadeným uvoľňovaním farmaceuticky akceptovateľných solí metoprololu a spôsob ich prípravy